DOCSLIB.ORG

Past Research Sponsors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Past Research Sponsors Via Christi Research sponsors AAFP Guidant PDL BioPharma Abbott Laboratories Guilford Penumbra Abbott Vascular Devices Guy's & St. Thomas' Charity Pfizer Abgenex Health Research Associates Pharmacia & Upjohn Acadia Pharmaceutical HeLP Pharmanet Achillion Hoechst Marion Roussel Proctor & Gamble Addex Hoffman-LaRoche Progenics Advanced Tissue Sciences Icagen Purdue Pharma Alexion Inhibitex Queens University Ontario Alsius Innapharma Reckitt-Benkiser Altana Innercool Therapies Red Cross Alza Inspire Pharmaceuticals Reid-Rowell Amgen Intarcia Rhone-Poulenc Rorer Amylin Pharmaceuticals Intermune Roche Anaclim Interneuron Sage ANI Inveresk Research Sandoz ApaTech IsoClear Sanofi-Aventis ASPEN ESPEN Jarvik Heart, Inc. Sanofi-Synthelabo Astellas Pharma Johns Hopkins University Schwarz Biosciences AstraZeneca Johnson & Johnson Scios AtheroGenics Kansas Bioscience Authority Searle Auxilium Pharmaceuticals Kansas Health Institute Sention Aventis Pharmaceuticals Kansas Surgery & Recovery Center Sepracor Avexa Koronis Pharmaceuticals Shire Pharmaceutical Development Bayer Lifecore Biomedical SK BioPharma BD Diagnostics Lilly Smith & Nephew Blanchette-Rockefeller Neuroscience Institute Lundbeck Solvay Pharmaceuticals BioLine Rx MacroGenics Somerset BioRexis Pharmaceutical Marion Merrell Dow Southern Research Biovail Laboratories Medex Stryker Boehringer Ingelheim Pharmaceuticals Medical Technology Management Institute Synthes Boston Scientific Medicure Sucampo Pharmaceuticals Bristol-Myers Squibb Medtronic Sumitomo Pharmaceuticals Burroughs Wellcome Medtronic Sofamor Danek Sunovion Capitol Health Merck SUNY Buffalo CardioDx MGI Pharma Supernus CardioMems Miles Syntex CASG Minnesota Epilepsy Group Synthes Spine Centocor Moffitt Cancer Center & Research Institute Takeda Pharmaceuticals Cephalon MyeloRx Tibotec Columbia University Nabi Biopharmaceuticals TriPath Imaging Community Research Initiative/New England NephroGenex UCB Pharma Cordis Neurovascular Neurochem United BioSource Corus Pharma Neurogen United States Navy Cubist NeuroPace University of Arizona CVRx Neurosearch University of California Los Angeles CV Therapeutics Nordmark University of California San Diego Cyberonics Northwestern U University of Chicago Cystic Fibrosis Foundation Therapeutics NovaCardia University of Kansas Cytokine PharmaSciences Novartis Pharmaceuticals University of Massachusetts Daichii Sankyo Novo Nordisk University of Minnesota Daiichi Asubio Pharmaceuticals Nuvelo University of Nebraska Debiopharm Omnicare University of North Carolina Discovery Laboratories OnoPharma University of Rochester Eisai Optimer University of Texas Southwestern Emory University Oregon Aero University of Washington EnVivo Organon Upjohn Fibrogen Orion Pharma VAC Kinetic Forest Laboratories Ortho-McNeil Janssen Valeant Pharmaceuticals Fujisawa Healthcare Orthopaedic Research & Education Foundation Vertex Genentech Otsuka America Pharmaceutical Wallace Labs Gilead Sciences Pacific Research Institute World Heart GlaxoSmithKline Paratek Worldwide Clinical Trials GraceMed Health Clinic Parke-Davis Wyeth Research Zars .
Load more

Recommended publications
  • Essex Hangar Aircrafi: Challenger (Schering Plough) Tail Number: N34CD Flight Time: 50 Minutes
    This document is from the collections at the Dole Archives, University of Kansas http://dolearchives.ku.edu ... DRAFT# 1- 8/26/94 ·- Contact: Mo Taggart 703/684-7848 Jo-Anne Coe 703/845-1714 SENATOR DOLE SCHEDULE ~ AUGUST 30, 1994 -NEW YORK TUESDAY. AUGUST 30 .. 1".4 10:35 am DEPART Capitol for National Airport Ori ver: Wilbert 10:50 am ARRIVE National Airport and proceed to departing aircraft PBO: Signature 703/419·8440 10:55 am DEPART Wushington for Morristown, NJ FBO: Essex Hangar Aircrafi: Challenger (Schering Plough) Tail number: N34CD Flight time: 50 minutes Pilots: Curt Barsi John Santucci Seats: 6 Meal: None Manifest: Senator Dole Rob Lively, Schcring Plough Mike Glassner • Mark Miller Contact: Rob Lively 202/463-8809 11:45 am ARRIVE Morristown, NJ FBO: Essex Hangar 201/539-6554 11 :50 am DEPART airport for Shering Plough Headquarters Driver: Mr. Luciano's driver Drive time: 5 minutes J,ocation: l Giralda Fanns Madison, NJ 11 :55 am ARRIVE Schering Plough Headquarters 20 I /822-7440 Page 1 of 48 This document is from the collections at the Dole Archives, University of Kansas http://dolearchives.ku.edu TUESDAY, AUGUSI-.3D .1994 PAGE TWO 12:00 N- ATTEND Lunch with Bob Luciano, Chairman of Schering Plough 1:30 pm 1:30 pm DEPART Schering Plough Headquarters for airport Driver: Mr. Luciano's driver Drive time: 5 minutes 1:35 pm ARRIVE airport and proceed to departing heliocopter FBO: Essex Hangar 201/539-6554 1:40 pm DEPART Morristown, NJ for New York Helo pad: 34th Strecf Helo pad Aircraft: S-76 .
    [Show full text]
  • In the United States District Court for the District Of
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABORATORIES, LLC and ) FOREST LABORATORIES ) HOLDINGS, LTD., ) ) Plaintiffs, ) ) v. ) Civ.No.14-1119-SLR ) SIGMAPHARM LABORATORIES, LLC, ) et al., ) ) Defendants. ) Jack B. Blumenfeld, Esquire and Maryellen Noreika, Esquire of Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware. Counsel for Plaintiffs. Of Counsel: Howard W. Levine, Esquire, Sanya Sukduang, Esquire, Jonathan R. Davies, Esquire, Courtney B. Gasp, Esquire, and Charles E. Lipsey, Esquire of Finnegan, Henderson, Farabow, Garrett & Dunner LLP. John C. Phillips, Esquire, David A. Bilson, Esquire and Megan C. Haney of Phillips, Goldman, Mclaughlin & Hall, P.A., Wilmington, Delaware. Counsel for Defendant Sigmapharm Laboratories, LLC. Of Counsel: Anthony G. Simon, Esquire, Anthony R. Friedman, Esquire, Benjamin R. Askew, Esquire, and Michael P. Kella, Esquire of The Simon Law Firm, P.C. Karen Elizabeth Keller, Esquire and Jeffrey Thomas Castellano, Esquire of Shaw Keller, LLP, Wilmington, Delaware. Counsel for Defendants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, and West-Ward Pharmaceutical Corp. Of Counsel: lmron T. Aly, Esquire, Joel M. Wallace, Esquire, and Helen H. Ji, Esquire of Schiff Hardin LLP. Richard D. Kirk, Esquire, Stephen B. Brauerman, Esquire and Sara E. Bussiere, Esquire of Bayard, P.A., Wilmington, Delaware. Counsel for Defendant Breckenridge Pharmaceutical, Inc. Of Counsel: Beth D. Jacob, Esquire, Clifford Katz, Esquire, and Malavika A. Rao, Esquire of Kelley, Drye & Warren LLP. Karen Pascale, Esquire and Pilar G. Kraman, Esquire of Young, Conaway, Stargatt & Taylor, LLP, Wilmington, Delaware. Counsel for Defendants Alembic Pharmaceuticals Ltd., Alembic Global Holding SA and Alembic Pharmaceuticals, Inc. Of Counsel: Steven J. Lee, Esquire, Michael K.
    [Show full text]
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Assessment Report COVID-19 Vaccine Astrazeneca EMA/94907/2021
    29 January 2021 EMA/94907/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report COVID-19 Vaccine AstraZeneca Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ........................................................................................ 12 2.1.2. Epidemiology and risk factors ........................................................................... 12 2.1.3. Aetiology and pathogenesis .............................................................................
    [Show full text]
  • Fibrolase: Trials and Tribulations
    Toxins 2010, 2, 793-808; doi:10.3390/toxins2040793 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Fibrolase: Trials and Tribulations Francis S. Markland 1,2,* and Steve Swenson 1,2 1 Department of Biochemistry and Molecular Biology, Cancer Research Laboratory, Keck School of Medicine, University of Southern California, 1303 N. Mission Rd., Los Angeles, CA 90033, USA 2 USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-(323) 224-7981; Fax: +1-(323) 224-7679. Received: 11 March 2010; in revised form: 31 March 2010 / Accepted: 19 April 2010 / Published: 20 April 2010 Abstract: Fibrolase is the fibrinolytic enzyme isolated from Agkistrodon contortrix contortrix (southern copperhead snake) venom. The enzyme was purified by a three-step HPLC procedure and was shown to be homogeneous by standard criteria including reverse phase HPLC, molecular sieve chromatography and SDS-PAGE. The purified enzyme is a zinc metalloproteinase containing one mole of zinc. It is composed of 203 amino acids with a blocked amino-terminus due to cyclization of the terminal Gln residue. Fibrolase shares a significant degree of homology with enzymes of the reprolysin sub-family of metalloproteinases including an active site homology of close to 100%; it is rapidly inhibited by chelating agents such as EDTA, and by alpha2-macroglobulin (). The enzyme is a direct-acting thrombolytic agent and does not rely on plasminogen for clot dissolution. Fibrolase rapidly cleaves the A()-chain of fibrinogen and the B()-chain at a slower rate; it has no activity on the -chain.
    [Show full text]
  • Guidelines on CVD During Pregnancy (TF17) - Task Force Members and Additional Contributors
    Guidelines on CVD during Pregnancy (TF17) - Task Force Members and Additional Contributors Expert Relationship Type of relationship with industry Financial declaration with Industry Blomstrom-Lundqvist Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. Carina - Medtronic : Pacemaker B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Atricure : AF ablation Borghi Claudio Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini International : ACE-inhibitors - Boheringer Ingelheim : Antihypertensive drugs - Recordati International : Antihypertensive drugs - Novartis : Antihypertensive, Heart Failure D - Research funding (departmental or institutional). - Barilla Food Company : Lactotripeptides Cifkova Renata Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : cardiovascular - Daiichi Sankyo : cardiovascular - MSD-SP, Boehringer Ingelheim, Bayer : cardiovascular B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular - Novartis : cardiovascular D - Research funding (departmental or institutional). - Krka Czech Republic : cardiovascular - Servier Czech Republic : cardiovascular Ferreira J Rafael No
    [Show full text]
  • Numeric Listing of Manufacturers That Have Signed Rebate Agreements
    Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements January 1, 2020 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00172 IVAX PHARMACEUTICALS, INC. 1/1/1991 Y 00003 E.R. SQUIBB & SONS, LLC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 00004 HOFFMANN-LA ROCHE 1/1/1991 00178 MISSION PHARMACAL COMPANY 1/1/1991 00006 MERCK & CO., INC. 1/1/1991 Y 00182 GOLDLINE LABORATORIES, INC. 1/1/1991 00007 GLAXOSMITHKLINE 1/1/1991 00185 EON LABS, INC. 1/1/1991 Y 00008 WYETH LABORATORIES 1/1/1991 Y 00186 ASTRAZENECA PHARMACEUTICAL 1/1/1991 Y 00009 PHARMACIA AND UPJOHN COMPA 1/1/1991 Y 00187 BAUSCH HEALTH US, LLC. 1/1/1991 Y 00013 PHARMACIA AND UPJOHN COMPA 1/1/1991 Y 00206 WYETH PHARMACEUTICALS LLC 1/1/1991 Y 00015 MEAD JOHNSON AND COMPANY 1/1/1991 Y 00224 KONSYL PHARMACEUTICALS, INC. 1/1/1992 00023 ALLERGAN INC 1/1/1991 00225 B. F. ASCHER AND COMPANY, INC. 1/1/1991 00024 SANOFI-AVENTIS, US LLC 1/1/1991 Y 00228 ACTAVIS ELIZABETH LLC 1/1/1991 Y 00025 GD. SEARLE LLC DIVISION OF PFIZ 1/1/1991 Y 00245 UPSHER-SMITH LABORATORIES, I 1/1/1991 Y 00026 BAYER HEALTHCARE LLC 1/1/1991 Y 00254 PAR PHARMACEUTTICAL INC. 9/28/2018 00029 GLAXOSMITHKLINE 1/1/1991 00258 FOREST LABORATORIES INC 1/1/1991 00032 ABBVIE INC. 1/1/1991 Y 00259 MERZ PHARMACEUTICALS 1/1/1991 00037 MEDA PHARMACEUTICALS, INC.
    [Show full text]
  • 2019 National Capacity Assessment Report
    National Capacity Assessment Report Pursuant to CERCLA Section 104(c)(9) December 17, 2019 U.S. Environmental Protection Agency [Page intentionally left blank.] Acronyms Used in this Report BIFs Boilers and Industrial Furnaces BR Biennial Report or Hazardous Waste Report BTU British Thermal Unit CA Cooperative Agreement CAP Capacity Assurance Plan CERCLA Comprehensive Environmental Response, Compensation, and Liability Act CFR Code of Federal Regulations EPA U.S. Environmental Protection Agency EPA ID EPA Identification Number FR Federal Register GM Form Waste Generation and Management Form LQG Large Quantity Generator RCRA Resource Conservation and Recovery Act, as amended SARA 1986 Superfund Amendments and Reauthorization Act SQG Small Quantity Generator SSC State Superfund Contract TSDFs Treatment, Storage, and Disposal Facilities VSQG Very Small Quantity Generator WR Form Waste Received from Offsite Form [Page intentionally left blank.] Table of Contents Executive Summary .................................................................................................................. i 1. Introduction ................................................................................................................. 1 Background..................................................................................................................................... 1 Purpose and Organization of Report .............................................................................................. 3 2. Data Development ......................................................................................................
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • Obesity, Diabetes, & Diet
    Obesity, Diabetes, & Diet COMBINING EVIDENCE FOR ALL THREE INTO IMPROVED PATIENT CARE Case Study Louis J. Aronne, MD, FACP Weill Cornell Medical College Columbia University College of Physicians and Surgeons Louis J. Aronne, MD, FACP Disclosures !! Research/Grants: Amylin Pharmaceuticals, Inc.; Arena Pharmaceuticals, Inc.; F. Hoffmann-La Roche, Ltd.; Metabolous Pharmaceuticals, Inc.; Norvo Nordisk; Orexigen Therapeutics, Inc.; Pfizer Inc.; TransTech Pharma, Inc. !! Speakers Bureau: None !! Consultant: Allergan, Inc.; Amylin Pharmaceuticals, Inc.; GI Dynamics, Inc.; GlaxoSmithKline Consumer Healthcare, LP; Johnson & Johnson Pharmaceutical Research & Development, LLC; NeuroSearch, Inc.; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche Laboratories, Inc.; VIVUS, Inc.; Wyeth Pharmaceuticals, Inc. !! Stockholder: Cardiometabolic Support Network, LLC !! Other Financial Interest: None !! Advisory Board: Allergan, Inc.; Amylin Pharmaceuticals, Inc.; GI Dynamics, Inc.; GlaxoSmithKline Consumer Healthcare, LP; Johnson & Johnson Pharmaceutical Research & Development, LLC; NeuroSearch, Inc.; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche Laboratories, Inc.; VIVUS, Inc.; Wyeth Pharmaceuticals, Inc. Father A.V. 04May09: 378 lbs, 5’ 11”, BMI = 53 !! Dx w/ DMII in 2004 !! Long history of obesity !! Can’t control his eating, binges !! HbA1c = 8.4% !! FPG = 166 !! TG = 241 !! UA Microalbumin = 973 !! “Can’t tolerate metformin” !! Considering RYGB, but afraid to have surgery DMII = diabetes mellitus type II; Hb = hemoglobin; FPG = fasting plasma glucose;
    [Show full text]
  • REFERENCE DOCUMENT Including the Sustainable Development Report Contents
    2015 REFERENCE DOCUMENT Including the Sustainable Development Report Contents Key Figures 2 1 Management Report 9 4 Financial statements 199 History of the Air Liquide Group 10 Consolidated fi nancial statements 201 Activities and risk factors 15 Statutory accounts of the parent company 275 2015 Performance 32 Investment cycle and fi nancing strategy 45 Innovation 53 Strategy and outlook 62 5 Annual General Meeting 2016 297 Board of Directors’ Report on the resolutions presented to the 2016 Combined Shareholders’ 2 2015 Corporate Social Responsibility Meeting 298 and Sustainable Development Report 65 Resolutions presented for the approval of the Combined Shareholders’ Meeting – Introduction 66 May 12, 2016 307 Our 2015 Social and Environmental Contribution 67 Statutory Auditors’ Reports 327 Environmental, social and governance (ESG) report 69 Reporting methodology 113 Independent verifi er’s report 115 Appendix 118 6 Additional information 339 Share capital 340 General information 346 3 Corporate governance 119 Trade payables 356 Factors that may have an impact in the event Management and control 120 of a takeover bid 357 Report from the Chairman of the Board of Directors 123 Person responsible for the Reference Document 359 Remuneration of the Executive Offi cers and Directors Cross-reference table for the Reference Document 360 of L’Air Liquide S.A. 147 Cross-reference table for the Annual Financial Report 364 Statutory Auditors’ Report 174 Cross-reference table for the Management Report 365 Transactions involving Company shares performed
    [Show full text]